Google
The 3-year overall survival (OS) and progression-free survival (PFS) were 41% and 21%, respectively. Adverse OS was associated with chemoresistant disease ( ...
The purpose of the present study was to establish evidence of efficacy and to identify clinically important prognostic factors. Patients, materials, and methods.
Jun 1, 2005 · With a median follow-up of 28 months, 115 patients are alive (range, 1-53 months). The estimated overall survival at 3 years is 40.6% (CI, 33%- ...
The 3-year overall survival (OS) and progression-free survival (PFS) were 41% and 21%, respectively. Adverse OS was associated with chemoresistant disease ( ...
Grades II to IV acute graft-versus-host disease (aGvHD) occurred in 31%. Chronic GvHD was associated with better OS and PFS and were 84% and 46% for limited, 58 ...
Nov 1, 2005 · The overall survival (OS) and progression-free survival (PFS) at 3 years were 58% (CI, 50%-66%) and 37% (CI, 30%-45%), respectively.
Missing: multiple myeloma
Overall, 12 patients (23%) achieved CR and 26 patients (51%) achieved PR, with an overall response rate of 74% after RIC allo-HSCT. Three patients (6%) had ...
People also ask
What is the best prognostic factor for multiple myeloma?
Traditional prognostic factors in MM measure plasma cell proliferation (plasma cell labeling index, Ki-67), plasma cell mass (clinical stage, plasmacytosis), or the status of the patient (hemoglobin, calcium, creatinine, albumin).
What is the prognostic indicator for multiple myeloma?
Beta-2-microglobulin is a protein found on the surface of myeloma cells that plays a role in the immune response. A higher level of beta-2-microglobulin predicts a poor prognosis. The level of this protein goes up if: the number of myeloma cells goes up.
What is the prognosis for multiple myeloma autologous stem cell transplant?
The average survival time was 29.8 months and the median follow-up was 25.1 months. The 1-year OS and PFS were 93.3% and 90.0%, respectively. Both the 3-year OS and PFS were 76.7%. In a variety of factors, improved renal function showed a good effect on the outcome of transplantation.
Can allogeneic stem cell transplant cure multiple myeloma?
Allogeneic transplants might be better at fighting the cancer than autologous transplants, but they are much riskier. In studies of people with multiple myeloma, those who got allogeneic transplants have often done worse in the short term than those who got autologous transplants.
Cumulative transplantation-related mortality at 1 year was 25%. Progression-free survival (PFS) and overall survival (OS) at 2 years were 19% and 32%, ...
Aug 18, 2023 · This study demonstrates overall poor survival outcomes in patients who underwent allo SCT for treatment of multiple myeloma with long-term ...
Missing: Leukaemia | Show results with:Leukaemia
Jun 20, 2013 · Tandem autologous/reduced-intensity allogeneic transplantation is superior to autologous transplantation alone in multiple myeloma. Abstract.
Missing: Leukaemia | Show results with:Leukaemia